<SEC-DOCUMENT>0001171843-19-002746.txt : 20190430
<SEC-HEADER>0001171843-19-002746.hdr.sgml : 20190430
<ACCEPTANCE-DATETIME>20190430080100
ACCESSION NUMBER:		0001171843-19-002746
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190430
FILED AS OF DATE:		20190430
DATE AS OF CHANGE:		20190430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		19778540

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_043019.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 4pt 0 0"><B>UNITED STATES </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 12pt 0 0"><B>FORM 6-K </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Date of report: April 30, 2019 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="font-size: 24pt; text-align: center; margin: 12pt 0 0"><B>GENFIT S.A. </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(Translation of registrant&rsquo;s name into English) </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>59120 Loos, France</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(Address of principal executive office) </B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">&#9746; Form 20-F &#9;&#9744; Form 40-F</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 178.35pt 0pt 209.3pt; text-align: center"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>EXHIBIT LIST </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="exh_991.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="exh_991.htm">Press Release dated April 30, 2019</A>.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 178.35pt 0pt 209.3pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 178.35pt 0pt 209.3pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 178.35pt 0pt 209.3pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: #080808"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>SIGNATURES </B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: April 30, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jean-Fran&ccedil;ois Mouney</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name: Jean-Fran&ccedil;ois Mouney</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title: Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: #080808"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: #080808">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: #080808">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: #080808"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 102.2pt 0pt 0; text-align: right; color: #080808"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.95pt 0pt 33.3pt; text-indent: 0.15pt"><FONT STYLE="color: #1F1F1F"></FONT></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 10pt; color: #005578"><FONT STYLE="font-size: 12pt"><B>GENFIT: Reports
First quarter 2019 Financial Information </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B><I>(Unaudited financial information under IFRS)<BR>
</I></B></FONT></P>

<P STYLE="font-size: 18pt; margin: 0.05pt 0 0"><B></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-weight: normal">-</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.65pt">Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled &euro;314.1
million as of March 31, 2019</TD></TR></TABLE>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 10pt 0 6pt 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="color: #005278"><B>Lille (France), Cambridge (Massachusetts,
United States), April 30, 2019</B></FONT><B> &ndash; GENFIT (Nasdaq and Euronext: GNFT)</B>, a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases,
today announced its cash position as of March 31, 2019 and revenues for the first three months of 2019.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 12pt 0 0; color: #005278"><B>Cash position </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 12pt 0 0">As of March 31, 2019, the Company&rsquo;s cash and cash equivalents
amounted to &euro;314.1 million compared with &euro;255.2 million one year earlier.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 12pt 0 10pt">As of December 31, 2018, cash and cash equivalents totaled
&euro;207.2 million.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 10pt; color: #005278"><B>Revenues </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 10pt">Revenues for the first three months of 2019 amounted to &euro;1
thousand compared to &euro;37 thousand for the same period in 2018.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 10pt; color: #005278"><B>ABOUT GENFIT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 6pt 0 10pt"><FONT STYLE="font-size: 10pt">GENFIT is a late-stage biopharmaceutical
company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (&ldquo;RESOLVE-IT&rdquo;)
as a potential treatment for NASH, and GENFIT plans to initiate a Phase 3 clinical trial in PBC later this year following its
positive Phase 2 results. As part of GENFIT&rsquo;s comprehensive approach to clinical management of NASH patients, the company
is also developing a new, non-invasive and easy-to-access blood-based <I>in vitro </I>diagnostic test to identify patients with
NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the
Company has approximately 150 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment
B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext: GNFT). </FONT>www.genfit.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #706F61"><B>GENFIT</B> | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5.9pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 4.95pt 5.6pt 0 5.9pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0; color: #005578"><FONT STYLE="text-transform: uppercase"><B>FORWARD
LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 6pt 0 10pt">This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including
&ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;expect&rdquo; and &ldquo;will&rdquo; and similar expressions, is intended
to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and
reasonable assumptions of the Company&rsquo;s management, these forward-looking statements are subject to numerous known and unknown
risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected
by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research
and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials,
review and approvals by regulatory authorities of its drug and diagnostic candidates and the Company&rsquo;s continued ability
to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company&rsquo;s
public filings with the French Autorit&eacute; des march&eacute;s financiers (&ldquo;AMF&rdquo;), including those listed in Section
4 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s 2018 Registration Document filed with the AMF on February 27,
2019 under n&deg; D.19-0078, which is available on GENFIT&rsquo;s website (www.genfit.com) and on the website of the AMF (www.amf-france.org)
and public filings and reports filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;), including the Company&rsquo;s
final prospectus dated March 26, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public,
by the Company. In addition, even if the Company&rsquo;s results, performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results
or developments in future periods. These forward-looking statements speak only as of the date of publication of this document.
Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking
information or statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0; color: #005578"><FONT STYLE="text-transform: uppercase"><B>CONTACT</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 6pt 0 10pt"><B>GENFIT</B> | Investors</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="font-size: 10pt">Naomi EICHENBAUM &ndash; Investor Relations
| Tel: +1 (617) 714 5252 | </FONT>investors@genfit.com</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; color: #005578"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 10pt"><B>PRESS RELATIONS | </B>Media</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="font-size: 10pt">H&eacute;l&egrave;ne LAVIN &ndash; Press
relations | Tel: +333 2016 4000 | </FONT>helene.lavin@genfit.com</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 4.95pt 5.6pt 0 5.9pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5.9pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #706F61"><B>GENFIT</B> | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. TP# 2(  A$! Q$!_\0
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MJ@FP3BJ_FFGC<PYKMI*R.">Y6E! XJE-(0,&M&5"!6?<QY4FMTR&8]V^0U9
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M):V4T!D2%R25RP]2:RE2U2UU]#98EV;TT\W_ )'4?\)#HF/^0Q89_P"OE/\
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M*0?6M&'5-/\ M1FN+W$MP,*9QNB?TY[&J!HP"F1FFA*V]:TK[!;P7L;PM;7
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MQ0S>1<>2I(\SR^!@X/->M&M2@DXNUM/N/.E3J3NFOZ9XA=?#+Q1;S,BZ>+A
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M3R'_ /9:Z\>W:N7\7Q;[FP]@_P#[+5IV(:NC'LF? ))K6CER *H01\"M&&/
MZ5R3F[G32@DB2HI >:L!<TUTXZ5GS,W4$4,D-2GIFGR+CM47.,5I"3,:M/0:
MSX/6@3+44@-,4&N^&J.!JQ*]Q@&D6\..],9.*@*G/2K:N0S5CF)[U.) 1UK+
MCFXP*LI)]:Y'5.M4M"YOH+C%1HP:D=#BKA4N1*%A^\&G"JQR*57(ZFMT8LL9
MQ4B/5;=3@^.]#0)EEG%,QOX'X\]!ZU'NW<5ROC#Q,-,A-C:$O<OP=O7Z>U0R
MUJ3:UJLER)[+39%#0QF2:8G 4#TK$T&T^TZ+<^;J#V4%T.6_Y:2#G\A6+;>)
MX_#=E^ZBCO;^[!^T3/RB?[(]<5AZC;ZO<:1+J]W<_9K4\1QD[6?V ';_ !K,
MT1H1>'9M&N//U)HI;+<3&J2;O,7T-1>(+B_\8B"-!:6&GP_)#$3M"^^!7)K>
M7']G[3*S+CA2Q^6I;/1M6OM+FU)"/LT/!=SC/T!HL.[M8NZMX>U'1+0F91+"
M0!YT)W+6=H6E'6M0%LLJQQ'EY2>![4RQUV_TYU$4Q9#UB;E6_"M&XU&"9FNH
M(%M3CYE3CYJ6H*QG:K;1:;JDEO;7!D2/I)GO5NUUNYF@%K<8G3^%G&67Z&J0
MT^2\1IA/'O/)#'&:<NGW-I T[H3&O\:\XIC'7;I>SA/.*A. #ZTV'1+J9QY+
M)*!V4\UF$EF+\\\\5?2&^L;2&^.Y(7/[MP<$FA^1*UW(+[?'<&!U:-X^-K<$
M&I-/M+R]E,=HC22@%B!V [UJMJ]MK,0CU:,&91A9T&&_'UIVFW3Z/!<&R)+2
M*5W_ ,1!HN597(+36Y(8WL[Z,7%N?E9&Y(]Q4;Z?9^?'+:S^9 2/W9ZCVK(<
M,I/F @YSR*M64AA1I<\XHM<.9FGXHU;^T)X(_+$45O&$5,<?6L5'8R 1L03Z
M5:BU)@W[Q%D7^ZPK1M3HUVP6:(V\I/WU/ I;"W*DM[Y:)$ZAP/O ]ZLV\>B7
MSHDP>S<_\M%Y7/O5/5=,N;&8L2)K<_<E09&*M:-H/]IZ=>7TLZPV]LFXDG!8
M\\ 4= 5[DFK:3-IT"O ZW%MG/G1_U%9$*&>58T0L[MA>^2:GM-3GM&*[B4Z%
M3R"*TK"6T:_2\@3RGC^;\:=M!Z,'?5/"]\L(N'20J&95/ SV(J2YN;35U$_$
M%Z2 Y' 8?2HM1@U/5;V6^*&?=U93SCMQ6?#;R1W.)D:(KR=XQ1L!Z'XRO=(F
M\(Z=86=JJSQX)=$Y)[DFN0T:=;ZX@T>Z8L)90(F(P5;VI+7Q%?Z;>>=;,"%X
MQ(,@UTUEXRT.]O(;K4=$MXKV+D3P +SZD4-L=DSJ/$]IH7A>;3[*%Y7M)"%N
MX2Q;:W]Y2?Y5CW]C;PLDUE<+<6LGW6Z$>QK)OO$-[IU])//%'?:=='.7&['^
M!KK+?Q#HWB'PS%I]E8K!<6[9*( &(/?WZ4(AV.9,0//>B.#<X'J:O7-LUO,T
M4J,K 9 88)%.LT4W*#WIB.\\/V"P:='M7D]:Z&*V]JK:1'BU3Z5K*,4 -2
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MROK%5-V>C;?Z&3=Z.+^\:>:XD 5-B)'Q@?Q9]<TQM$9M,6Q>X+QQS!D8KD[
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M1]H\0_\ 0+TS_P &,G_QBM?;[4[;[4<R[!RR_F?]?(R!<>(O^@7IG_@QD_\
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M\=M/%_CZQL(+2+PLQCAC6-2VGSY(  R?F]JL_%33-4U6?2);73;JX(@;S!!
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MTTS'N* )\4QA3/.)[4;^10 [E:/,('>F[J"3BBX#0[-(/K7T7X13'A?3,_\
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GR.-F=G/S(Z&UN0P'-7U<E<US]BK!QS6_&"4'-;TV[:G-42OH?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
